An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Assess the Effect of Steady-State Branebrutinib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jun 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Branebrutinib (Primary) ; Rosuvastatin
Indications Atopic dermatitis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
Focus Pharmacokinetics
Sponsors Bristol-Myers Squibb

04 Jun 2022 Results assessing the DDI potential of branebrutinib when co-administered with potential concomitant medications in 3 single-sequence, cross-over clinical studies in healthy participants presented at the 23rd Annual Congress of the European League Against Rheumatism
25 Feb 2022 Status changed from not yet recruiting to completed.
18 Aug 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com